Oct 29, 2018   SOURCE: PR NewsWire

Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5

TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed? or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol(TM), a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that it will host a conference call and webcast on Monday, November 5, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol(TM) and to discuss financial results for the three and nine months ended September 30, 2018.

https://mma.prnewswire.com/media/595923/Galmed_Pharmaceuticals_Ltd_Logo.jpg


       
              
                Conference Call & Webcast:





       
              
                
                  Monday, November 5 @ 8:30am Eastern Time

    ---




       Within the US:                                              
            800-239-9838



       Outside the US:                                             
            323-794-2551



       From Israel:                                                                                                        
            1809 212 883



       Conference ID:                                                                                                                    9320949



       Webcast:                                                    
            
              http://public.viavid.com/index.php?id=131686





       
              Replays, Available through November 19:





       Domestic:                                                   
            844-512-2921



       International:                                              
            412-317-6671



       Replay PIN:                                                                                                                       9320949

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.

View original content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-third-quarter-2018-financial-results-and-provide-business-update-on-monday-november-5-300739290.html

SOURCE Galmed Pharmaceuticals Ltd.